Ruben G W Quek
Overview
Explore the profile of Ruben G W Quek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1415
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harnett J, Heidt J, Quek R, Walsh L
Clin Pharmacol Ther
. 2024 Oct;
117(1):24.
PMID: 39350739
No abstract available.
2.
Oderda G, Brixner D, Biskupiak J, Harnett J, Chen C, Quek R
J Manag Care Spec Pharm
. 2024 Aug;
30(8):825-833.
PMID: 39088340
Background: There is limited knowledge of how US managed care professionals view and prioritize quality metrics/performance measures, care models, alternative payment models, and clinical pathways in oncology settings. Objective: To...
3.
Peris K, Inocencio T, Stratigos A, Lewis K, Eroglu Z, Chang A, et al.
Cancer Med
. 2024 Jul;
13(14):e7360.
PMID: 39031963
Background: A phase 2 cemiplimab study (NCT03132636) demonstrated a 24.1% objective response rate in patients diagnosed with metastatic basal cell carcinoma (mBCC) who were not candidates for continued hedgehog inhibitor...
4.
Johnson P, Bailey A, Ma Q, Milloy N, Butcher J, Sanderson I, et al.
Front Oncol
. 2024 Jul;
14:1402992.
PMID: 38978741
Background: Real-world health-related quality of life (HRQoL) data in patients with diffuse large B-cell lymphoma (DLBCL) are scarce. This study is to compare patient-reported outcomes in patients with DLBCL across...
5.
Johnson P, Bailey A, Ma Q, Milloy N, Biondi E, Quek R, et al.
Adv Ther
. 2024 Jul;
41(8):3342-3361.
PMID: 38976122
Introduction: Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin's lymphoma (NHL), characterized by a long natural course of remissions/relapses. We aimed to evaluate real-world quality of life (QoL) in...
6.
Baramidze A, Makharadze T, Gogishvili M, Melkadze T, Giorgadze D, Penkov K, et al.
Lung Cancer
. 2024 May;
193:107821.
PMID: 38820979
Objectives: EMPOWER-Lung 3 part 2 (NCT03409614), a double-blind, placebo-controlled phase 3 study, assessed cemiplimab (anti-programmed cell death protein 1) plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell...
7.
Huml R, Collyar D, Antonijevic Z, Beckman R, Quek R, Ye J
Ther Innov Regul Sci
. 2023 Aug;
57(6):1136-1147.
PMID: 37615880
Master protocols (MPs) are an important addition to the clinical trial repertoire. As defined by the U.S. Food and Drug Administration (FDA), this term means "a protocol designed with multiple...
8.
Makharadze T, Quek R, Melkadze T, Gogishvili M, Ivanescu C, Giorgadze D, et al.
Cancer
. 2023 May;
129(14):2256-2265.
PMID: 37151113
Background: EMPOWER-Lung 3, a randomized 2:1 phase 3 trial, showed clinically meaningful and statistically significant overall survival improvement with cemiplimab plus platinum-doublet chemotherapy versus placebo plus chemotherapy for first-line treatment...
9.
Feliciano J, McLoone D, Xu Y, Quek R, Kuznik A, Pouliot J, et al.
Front Oncol
. 2023 Apr;
12:1081729.
PMID: 37082098
Objectives: In randomized-controlled crossover design trials, overall survival (OS) treatment effect estimates are often confounded by the control group benefiting from treatment received post-progression. We estimated the adjusted OS treatment...
10.
Sola-Morales O, Curtis L, Heidt J, Walsh L, Casso D, Oliveria S, et al.
Clin Pharmacol Ther
. 2023 Apr;
114(2):325-355.
PMID: 37079433
Real-world data (RWD)-derived external controls can be used to contextualize efficacy findings for investigational therapies evaluated in uncontrolled trials. As the number of submissions to regulatory and health technology assessment...